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OBJECTIVES We sought to elucidate the long-term prognostic importance of angiographic no-reflow
phenomenon after percutaneous transluminal coronary angioplasty (PTCA) for acute
myocardial infarction (AMI).
BACKGROUND Angiographic no-reflow phenomenon, a reduced coronary antegrade flow (Thrombolysis in
Myocardial Infarction [TIMI] flow grade #2) without mechanical obstruction after recan-
alization, predicts poor left ventricular (LV) functional recovery and survival in the early phase
of AMI. We hypothesized that angiographic no-reflow phenomenon also predicts long-term
clinical outcome.
METHODS We studied 120 consecutive patients with their first AMI treated by PTCA without
flow-restricting lesions. The patients were classified as either no-reflow (n 5 30) or reflow
(TIMI-3) (n 5 90) based on post-PTCA cineangiograms to follow up (5.8 6 1.2 years) for
cardiac death and nonfatal events.
RESULTS Patients with no-reflow had congestive heart failure (p , 0.0001), malignant arrhythmia
(p 5 0.038), and cardiac death (p 5 0.002) more often than did those with reflow.
Kaplan-Meier curves showed lower cardiac survival and cardiac event-free survival (p ,
0.0001) in patients with no-reflow than in those with reflow. Multivariate analyses disclosed
that no-reflow phenomenon was an independent predictor of long-term cardiac death
(relative risk [RR] 5.25, 95% confidence interval [CI] 1.85 to 14.9, p 5 0.002) and cardiac
events (RR 3.71, 95% CI 1.79 to 7.69, p 5 0.0004). At follow-up, survivors with no-reflow
had higher end-diastolic and end-systolic LV volume indices and plasma brain natriuretic
peptide levels, and lower LV ejection fractions (p 5 0.0002, p , 0.0001, p 5 0.002, p ,
0.0001, respectively) than did those with reflow, indicating that no-reflow may be involved in
LV remodeling.
CONCLUSIONS Angiographic no-reflow phenomenon strongly predicts long-term cardiac complications after
AMI; these complications are possibly associated with LV remodeling. (J Am Coll Cardiol
2000;36:1202–9) © 2000 by the American College of Cardiology
It is well known that early restoration of coronary antegrade
flow limits the progression of myocardial necrosis; such
restoration is expected to enhance the functional recovery of
postischemic dysfunctioning myocardium in patients with
acute myocardial infarction (AMI) (1–3). However, recent
studies have demonstrated that successful reopening of an
occluded epicardial coronary artery does not necessarily lead
to left ventricular (LV) functional recovery; in fact, the
“no-reflow” phenomenon occurs in some cases (4,5). The
“no-reflow” phenomenon refers to the absence of myocar-
dial perfusion even after successful reopening of the infarct-
related artery (IRA) (6,7). This phenomenon has been
evaluated by various methods, including contrast echocar-
diography (5,8), scintigraphy (9,10), and cineangiography
(4,11) in patients with AMI. On angiograms, the no-reflow
phenomenon is defined as substantial coronary antegrade
flow reduction (less than Thrombolysis in Myocardial In-
farction [TIMI] flow grade 3) without mechanical obstruc-
tion (12).
We previously demonstrated that the “angiographic no-
reflow” phenomenon after percutaneous transluminal coro-
nary angioplasty (PTCA) predicts poor LV functional
recovery and a higher risk of cardiac mortality during the
early phase of disease in patients with AMI (4). Since that
report was published, the clinical importance of angio-
graphic no-reflow phenomenon has been well investigated
and established as it relates to AMI (11,13–17). However,
the long-term prognosis after AMI, which is strongly
associated with progressive LV dilation (18–20), remains
unexplored in patients with angiographic no-reflow. Con-
sequently, we further investigated the long-term prognostic
importance of the angiographic no-reflow phenomenon
after successful PTCA for AMI in terms of cardiac death
and nonfatal events, and LV function and remodeling in the
surviving patients.
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METHODS
Patient population. Of 476 consecutive patients with
AMI who were treated at the Department of Cardiology of
Ogaki Municipal Hospital between January 1990 and June
1994, 120 patients (79 men and 41 women) age 35 to 89
years were admitted to the study. Criteria for inclusion were:
1) initial episode of AMI; 2) a single-culprit lesion; 3) the
IRA was recanalized with direct or rescue-PTCA within 6 h
of the disease onset or between 6 h and 24 h if evidence
showed continuing ischemia; 4) residual stenosis not more
than 50%; and 5) absence of apparent dissection or throm-
bosis that might restrict coronary flow despite multidirec-
tional observations on cineangiograms. Patients excluded
from the study were those with concomitant severe diseases
such as chronic terminal renal failure and malignancy, those
with significant valvular heart disease, and those with the
culprit lesion in the left main trunk.
Assessment of angiographic no-reflow phenomenon.
Coronary angiograms were carefully reviewed by three
experienced investigators who were blinded to other param-
eters of the patients. The TIMI flow grades were deter-
mined by the consensus of the three investigators. Patients
were diagnosed as having angiographic no-reflow if they
developed substantial coronary flow reduction (TIMI flow
grade #2) in cineangiograms obtained at the end of PTCA
(No-Reflow group) (4,11,12). The Reflow group consisted
of the remaining patients with restored good coronary flow
(TIMI flow grade 3) after PTCA.
In-hospital clinical course. Adjunctive medical therapy
followed the standards of the coronary care unit. The
following data were obtained: age, gender, coronary risk
factors (hypertension, diabetes mellitus, hyperlipidemia, and
smoking), serum peak creatine kinase (CK) level, cardiac
complications, repeated PTCA, cardiac surgery, and LV
ejection fraction (LVEF). The serum peak CK levels were
determined among the serial samples obtained upon the
patient’s arrival and every 4 h following recanalization of the
IRA. Cardiac complications included recurrent AMI, ma-
lignant arrhythmia (excluding reperfusion arrhythmia), car-
diac rupture, pump failure, and death. Malignant arrhyth-
mia included sustained ventricular tachycardia, ventricular
fibrillation, or high degree atrioventricular block. Pump
failure was defined as Killip class $II or Forrester subset
$II. Follow-up coronary angiography was performed pre-
ceding patients’ discharge; when necessary, the patients
underwent additional PTCA or coronary artery bypass graft
surgery. The LVEF was determined by the last available
contrast left ventriculogram during index hospitalization
period.
Long-term follow-up. Patients were seen every month at
the outpatient clinic of Ogaki Municipal Hospital.
Follow-up data and cardiac function of the patients were
assessed in July 1998, by which time all patients had
completed the minimal follow-up period of four years
(mean 5.8 6 1.2 years).
Follow-up data included information about recurrent
AMI, malignant arrhythmia, congestive heart failure
(CHF) and/or unstable angina pectoris requiring hospital-
ization, repeated PTCA, cardiac surgery, and death. Data
were obtained from hospital charts and supplemented by the
patient’s general physicians as well as by a structured direct
interview or by a telephone interview with the patient or
with one of his or her immediate relatives; the interview was
conducted by cardiologists who were blinded to the patient’s
initial angiographic data. Deaths were classified as either
cardiac or noncardiac according to the diagnosis stated on
the patient’s death certificate. Diagnoses were further con-
firmed by information from hospital charts, patients’ general
physicians, or by immediate relatives of the patients. No
patient was lost to follow-up.
Assessment of cardiac function of the survivors. Cardiac
function of the survivors at the end of the study was also
assessed by the New York Heart Association (NYHA)
functional classification, echocardiography, and plasma
brain natriuretic peptide (BNP) levels. The NYHA func-
tional class was determined by direct interview or telephone
interview with patients. A single investigator blinded to
both clinical and angiographic data analyzed the echocar-
diograms. The LV volume was measured by the area-length
method (21); the volume index (volume/body surface area)
and LVEF were calculated to estimate LV remodeling.
Observer variability for LV volume analysis was assessed in
20 patients. The mean interobserver variabilities, which
were defined as the difference between two observers’
measurements, were 5.2 6 2.8% for LV end-diastolic
volume index (LVEDVI) and 6.3 6 4.2% for LV end-
systolic volume index (LVESVI). The mean intraobserver
variabilities, which were assessed by two independent mea-
surements one week apart, were 6.8 6 3.4% for LVEDVI
and 8.1 6 3.9% for LVESVI. Plasma BNP levels were
determined by a specific immunoradiometric assay kit of
Shiono RIA BNP (Shionogi, Osaka, Japan). The assay uses
two monoclonal antibodies that recognize the carboxyter-
minal sequence and the ring structure of human BNP,
respectively (22). Informed consent was obtained from each
patient.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
BNP 5 brain natriuretic peptide
CHF 5 congestive heart failure
CK 5 creatine kinase
IRA 5 infarct-related artery
LV 5 left ventricular
LVEDVI 5 left ventricular end-diastolic volume index
LVEF 5 left ventricular ejection fraction
LVESVI 5 left ventricular end-systolic volume index
MI 5 myocardial infarction
NYHA 5 New York Heart Association
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction trial
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Statistics. Continuous baseline and outcome variables are
expressed as mean 6 SD, whereas discrete variables are
given as absolute values, percentages, or both. Continuous
variables were compared with the Student two-tailed t test.
For comparison of rates of discrete outcome variables, the
chi-square test or the Fisher exact test was used. Differences
between subgroups in long-term cardiac survival and cardiac
event-free survival after patients’ discharge from the index
hospitalization were examined with the Kaplan-Meier
method and associated log-rank test. The composite out-
comes of the following cardiac events were employed in the
analyses: cardiac death, recurrent AMI, malignant arrhyth-
mia, and CHF requiring hospitalization. Multivariate anal-
yses of predictors of long-term cardiac and cardiac event-
free survival were performed using a Cox proportional-
hazards regression model. Forward-stepwise selection
method was used with inclusion criteria of a p value ,0.05
to identify the variables remaining as independent risk
factors for long-term survival. Variables included in the
analyses were age $70 years old, gender, multivessel disease,
anterior infarction, Killip class $II, serum peak CK levels
$3,000 IU/liter, LVEF #50%, and no-reflow. Among the
survivors during the index hospitalization period, those with
incomplete data were excluded from the multivariate mod-
els. Patients who had already had cardiac rupture and
recurrent myocardial infarction (MI) during their index
hospitalization period were also excluded from the analysis
of cardiac event-free survival. Finally, 111 and 109 patients
were included in the multivariate analyses of cardiac survival
and cardiac event-free survival, respectively. Data analyses
were performed by using the statistical software Stat View
5.0 (SAS Institute Inc., 1998). A p value of ,0.05 was
accepted as statistically significant.
RESULTS
Patient characteristics. Of 120 patients studied, angio-
graphic no-reflow phenomenon was present in 30 patients
(25%). Baseline and angiographic characteristics of the
patients are shown in Table 1. Compared with the patients
in the Reflow group, those in the No-Reflow group pre-
sented more often Killip class $II (p 5 0.0003) and anterior
wall infarction (p 5 0.0003). Age, ischemic time, collateral
grade, initial TIMI flow grade, and residual stenosis were
not different between the two groups. The similar propor-
tions of the no-reflow and reflow patients received
angiotensin-converting enzyme inhibitor (30% vs. 19%, p 5
0.201) and beta-blocker (0% vs. 7%, p 5 0.335).
In-hospital clinical course. Peak CK levels were signifi-
cantly higher in the No-Reflow group than in the Reflow
group (p , 0.0001) (Table 2). We observed more cardiac
complications, including pump failure (p , 0.0001), malig-
nant arrhythmia excluding reperfusion arrhythmia (p 5
0.048), and cardiac rupture (p 5 0.015) in the No-Reflow
group than in the Reflow group. Cardiac ruptures included
LV free-wall rupture in two patients and ventricular septal
perforation in one patient; the diagnosis was proven in all
cases during surgical closure of the ruptured site. The LVEF
was significantly lower in the No-Reflow group than in the
Reflow group (p , 0.0001). All patients who died during
their hospital stay were in the No-Reflow group; causes of
death were low output syndrome in two patients and
unsuccessful closure of the ruptured free wall in one patient.
Thus, cardiac mortality was significantly higher in the
No-Reflow group than in the Reflow group (p 5 0.015).
Long-term follow-up. The clinical complications that oc-
curred in both groups during the follow-up period are
shown in Table 3. We observed a significantly higher
incidence of malignant arrhythmia (excluding sudden
death) (p 5 0.038) and CHF requiring hospitalization (p ,
Table 1. Baseline Clinical and Angiographic Characteristics
of Patients
No-
Reflow
(n 5 30)
Reflow
(n 5 90) p Value
Age (yr) 68 6 14 63 6 12 NS
Male 20 (67%) 59 (66%) NS
Risk factors
Hypertension 16 (53%) 42 (47%) NS
Diabetes mellitus 8 (27%) 25 (28%) NS
Hyperlipidemia 8 (27%) 19 (21%) NS
Smoking 10 (33%) 52 (58%) 0.020
Ischemic time (hours) 6.0 6 4.7 5.7 6 5.3 NS
Killip class on admission
(class $II)
18 (60%) 22 (24%) 0.0003
Anterior infarction 25 (83%) 41 (46%) 0.0003
Initial TIMI flow grade
(grade 0)
25 (83%) 65 (72%) NS
Collaterals (Rentrop
grade #1)*
19 (68%) 43 (52%) NS
Multivessel coronary
artery disease
10 (33%) 27 (30%) NS
Residual stenosis (%) 36 6 12 35 6 15 NS
*Collaterals were not investigated before recanalization of infarct-related artery in two
patients from the No-Reflow group and in seven from the Reflow group because of
their critical condition. Data are presented as the number of patients (percent) or
mean value 6 SD.
NS 5 not significant; TIMI 5 Thrombolysis in Myocardial Infarction trial.
Table 2. In-Hospital Clinical Course
No-Reflow
(n 5 30)
Reflow
(n 5 90) p Value
Peak CK (IU/liter)* 4,271 6 3,111 2,362 6 1,595 , 0.0001
Recurrent AMI 1 (3%) 0 (0%) NS
Malignant arrhythmia 3 (10%) 1 (1%) 0.048
Cardiac rupture 3 (10%) 0 (0%) 0.015
Pump failure 24 (80%) 31 (34%) , 0.0001
Repeated PTCA 1 (3%) 18 (20%) 0.041
LVEF (%) 51.7 6 15.1 64.4 6 10.3 , 0.0001
Cardiac surgery 3 (10%)† 2 (2%)‡ NS
Cardiac death 3 (10%) 0 (0%) 0.015
*Data were excluded regarding patients who underwent cardioversion before identi-
fication of peak creatine kinase levels (three patients in each group). †Closure of
cardiac rupture; ‡coronary artery bypass graft surgery. Data are presented as the
number of patients (percent) or mean value 6 SD.
AMI 5 acute myocardial infarction; CK 5 creatine kinase; LVEF 5 left
ventricular ejection fraction; NS 5 not significant; PTCA 5 percutaneous translu-
minal coronary angioplasty.
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0.0001) in the No-Reflow group than in the Reflow group.
Of 27 patients who died during the follow-up period, 12
(44%) were in the No-Reflow group, and 15 (17%) were in
the Reflow group (p 5 0.003). Incidence of cardiac death
was also significantly higher in the No-Reflow group (37%)
than in the Reflow group (10%) (p 5 0.002); cardiac death
included three sudden deaths (one in the No-Reflow group
and two in the Reflow group). The prevalence of other
complications (recurrent AMI, unstable angina pectoris
requiring hospitalization, repeated PTCA, cardiac surgery)
was not significantly different between the two groups.
Long-term cardiac survival. Kaplan-Meier survival anal-
ysis revealed that the patients in the No-Reflow group had
a significantly higher incidence of cardiac death (log-rank
p , 0.0001) (Fig. 1). The other univariate significant
predictors of cardiac survival were LVEF #50% (p 5
0.0008), age $70 (p 5 0.0008), Killip class $II (p 5
0.0009), and anterior infarction (p 5 0.023). Peak CK levels
$3,000 IU/liter (p 5 0.058), multivessel disease (p 5
0.187) and gender (p 5 0.933) were not significant predic-
tors. Multiple stepwise Cox regression analysis identified
no-reflow (p 5 0.002) as an independent predictor followed
by age $70 years old (p 5 0.049) (Table 4).
Long-term cardiac event-free survival. Patients in the
No-Reflow group also had a significantly higher incidence
of cardiac events (log-rank p , 0.0001) (Fig. 2). The other
univariate significant predictors of cardiac event-free sur-
vival were Killip class $II (p 5 0.0001), LVEF #50% (p 5
0.0004), age $70 (p 5 0.037). Multivessel disease (p 5
0.063), anterior infarction (p 5 0.102), peak CK levels
$3,000 IU/liter (p 5 0.147), and gender (p 5 0.887) were
not significant predictors. Multivariate analysis also dis-
closed no-reflow as an independent predictor (p 5 0.0004)
followed by Killip class $II (p 5 0.020) (Table 4).
Cardiac function of the survivors at follow-up. At the
end of the follow-up period, 80 patients among 90 survivors
(89% of the survivors) continued to visit the outpatient
clinic of Ogaki Municipal Hospital. To assess the NYHA
functional class, we interviewed 84 patients (93%) directly
and 6 patients (7%) by telephone. We performed echocar-
diogram and measured plasma BNP levels in 83 patients
(92%); 13 of these patients were in the No-Reflow group
(88%); 70 of them were in the Reflow group (93%). Clinical
status of the survivors at follow-up is summarized in Table
5. One patient in the Reflow group was excluded from the
echocardiographic study because of inadequate image qual-
ity. Four patients in the Reflow group were not available for
NYHA classification, because they were bedridden due to
brain infarction (two patients), multiple vertebral metastasis
of prostate cancer (one patient), and severe spinal canal
stenosis (one patient). The prevalence of NYHA functional
class $III was significantly higher in the No-Reflow group
than in the Reflow group (p 5 0.0005). Both LVEDVI and
LVESVI were significantly higher in the No-Reflow group
than in the Reflow group (p 5 0.0002 and p , 0.0001,
respectively), indicating more advanced LV remodeling in
the former group. The LVEF was significantly lower in the
No-Reflow group than in the Reflow group (p , 0.0001).
Plasma BNP levels were significantly higher in the No-
Reflow group than in the Reflow group (p 5 0.002). When
the data concerning the patients who had experienced
recurrent AMI or cardiac rupture were excluded, significant
differences still existed between the two groups in relation to
LVEDVI, LVESVI, LVEF, and plasma BNP levels (data
not shown).
DISCUSSION
The results of the present study clearly demonstrated for the
first time the long-term prognostic value of the angio-
graphic no-reflow phenomenon after successful reopening
of the IRA in patients with AMI. Patients with no-reflow
more commonly experienced malignant arrhythmia, CHF,
and cardiac death than did those with reflow. They also had
more advanced LV remodeling, as shown on the echocar-
diographic findings. Angiographic no-reflow phenomenon
strongly predicts cardiac complications independent of
other well-known early predictors of long-term outcome
after AMI, such as age, Killip class, and LVEF.
Figure 1. Kaplan-Meier cardiac survival curves following the index hospi-
talization; a comparison of patients with no-reflow versus reflow.
Table 3. Cardiac Complications During Long-Term Follow-up
No-Reflow
(n 5 27)
Reflow
(n 5 90) p Value
Recurrent AMI 5 (19%) 14 (16%) NS
Malignant arrhythmia 3 (11%) 1 (1%) 0.038
Unstable angina pectoris 9 (33%) 15 (17%) NS
Congestive heart failure 11 (41%) 6 (7%) , 0.0001
Repeated PTCA 13 (48%) 47 (52%) NS
Cardiac surgery 1 (4%)* 2 (2%)† NS
Overall death 12 (44%) 15 (17%) 0.003
Cardiac death 10 (37%) 9 (10%) 0.002
*Reclosure of ventricular septal perforation; †coronary artery bypass graft surgery.
Data are presented as the number of patients (percent).
AMI 5 acute myocardial infarction; NS 5 not significant; PTCA 5 percutaneous
transluminal coronary angioplasty.
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Pathophysiology and clinical background of the angio-
graphic no-reflow phenomenon. The no-reflow phenom-
enon is defined as the occurrence of areas with heteroge-
neous or extremely low tissue flow after reopening the
occluded artery (6,7). The no-reflow phenomenon may be a
multifactorial condition reflecting damage to microvascular
integrity established both during ischemia and at the time of
reperfusion. Possible factors related include damage to
endothelial cells, tissue edema (7), neutrophil plugging of
the microvessels (23,24), and microvascular spasm (12,13).
Myocardial contrast echocardiography (i.e., echocardio-
graphic assessment of myocardial perfusion after intracoro-
nary injections of sonicated microbubbles) is a valid tech-
nique that has been used to describe myocardial reperfusion
after reopening the IRA in patients with AMI. The con-
sensus seems to have been reached that no-reflow detected
by myocardial contrast echocardiography is a predictor of
poor LV functional recovery and remodeling in the early
phase of AMI (5,8,25). Myocardial contrast echocardiogra-
phy, however, can be performed only in limited investiga-
tional settings, mainly because of procedural complexity.
The TIMI flow grade is the simplest alternative available
that assesses the no-reflow phenomenon, because neither
additional techniques nor extra time is required, other than
the cineangiograms obtained during PTCA. The TIMI
flow grade #2 without obstructive lesion of the vessel has
been generally regarded as the “angiographic no-reflow”
phenomenon (4,11,12); increased microvascular impedance
in the no-reflow zone may reduce epicardial coronary
antegrade flow. Recently, studies with a Doppler guide wire
demonstrated the distinctive altered flow pattern, possibly
reflecting increased downstream microvascular impedance,
in coronary arteries showing angiographic no-reflow phe-
nomenon (14,15). Further, Ito et al. (16) elucidated the link
between angiographic epicardial coronary flow and myocar-
dial contrast echocardiographic findings of myocardial per-
fusion at the microvascular level. They found that all
patients with TIMI flow grade 2 without obstruction after
successful PTCA showed defects in myocardial perfusion
(no-reflow). They concluded that TIMI flow grade 2 after
successful PTCA reflects advanced microvascular damage
and is a highly specific modality that can be used to detect
the no-reflow phenomenon (16). However, TIMI flow
grade 2 after thrombolytic therapy may not necessarily
indicate such microvascular damage. Inadequate coronary
patency may cause flow reduction even though downstream
vascular or muscle injury is less severe and microvasculature
is intact. Therefore, TIMI flow grade #2 after successful
PTCA without obstructive lesions, which we dealt with in
this study, should be regarded as an entity different from
that after thrombolytic therapy with probable residual ste-
nosis.
Relation of no-reflow phenomenon to LV remodeling
and cardiac complications. Progressive LV dilation after
AMI, an important feature of LV remodeling, is strongly
associated with adverse cardiovascular events, and it plays a
particularly important role in the development of CHF
(18–20). During the long-term follow-up period of the
present study, patients with no-reflow experienced CHF
more often than did those with reflow, rendering their
cardiac mortality much higher than those with reflow.
Moreover, even among the survivors, those with no-reflow
showed significantly higher LVEDVI and LVESVI, and
lower LVEF, than did those with reflow. These observa-
tions strongly suggest a link between no-reflow phenome-
non and LV remodeling.
Various factors have been considered as influential in LV
remodeling. These factors include infarct size, the perfu-
sional status of the IRA (19), asynergy (26), and increased
wall stress (18). In addition, Bolognese et al. (27) recently
contended that the transmural extent of myocardial necrosis
is necessary for LV expansion. In our previous study (4)
comparing patients with no-reflow and reflow, those with
no-reflow showed more extended transmural MI, which was
detected by scintigraphy, as well as more severely depressed
regional wall motion at three weeks after disease onset.
Figure 2. Kaplan-Meier cardiac event-free survival curves following the
index hospitalization; a comparison of patients with no-reflow versus
reflow. Cardiac events include cardiac death, recurrent acute myocardial
infarction, malignant arrhythmia, and congestive heart failure.
Table 4. Independent Predictors of Long-Term Event-Free Survival
Variables
Relative
Risk 95% CI
p
Value
Cardiac death No-Reflow 5.25 1.85–14.9 0.002
Age $70 years 2.85 1.01–8.08 0.049
Cardiac death 1 events No-Reflow 3.71 1.79–7.69 0.0004
Killip class $II 2.45 1.15–5.22 0.020
CI 5 confidence interval.
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These findings may provide support for the hypothesis that
the angiographic no-reflow phenomenon can be a predictor
of LV remodeling. These results also confirm and expand
on previous observations made by Ito et al. (25), who
discovered that no-reflow, as detected by myocardial con-
trast echocardiography, is associated with LV remodeling
one month after the onset of disease.
More recently, attention has been paid to injuries of the
myocardial collagen matrix in association with LV expan-
sion after AMI (28). Collagen forms an architectural scaf-
fold for the myocytes; in addition, it provides strength and
stiffness to the myocardium. The collagen is degraded by
extracellular matrix metalloproteases, enzymes normally
present in their latent form in the myocardium, but which
are activated by ischemia (29). Animal experiments have
demonstrated that reperfusion significantly attenuates in-
creased activity of matrix metalloproteases induced by isch-
emia in the infarct zone (30). Thus, theoretically, no-reflow
phenomenon, which indicates reperfusion failure, may lead
to extensive damage to the myocardial collagen matrix and
decrease myocardial strength and stiffness, resulting in
cardiac rupture and LV expansion.
The NYHA functional class was significantly higher in
the No-Reflow group than in the Reflow group among the
survivors at this study’s end point. Furthermore, plasma
BNP levels were also higher in the No-Reflow group than
in the Reflow group. The BNP has been established as a
very sensitive marker of LV dysfunction. Plasma BNP
concentrations have been shown to increase in proportion to
the degree of LV dysfunction in patients with chronic heart
failure (31) and with AMI (32). A decreased LVEF, higher
NYHA functional class, and elevated BNP levels indicate
severe LV dysfunction in patients with no-reflow in the
chronic stage.
Plasma BNP levels might have prognostic implications.
Recent studies have demonstrated that increased plasma
BNP levels in the early phase of AMI predicts long-term
poor cardiovascular mortality independent of well-known
predictors (33,34). It is not fully elucidated that plasma
BNP levels measured in the chronic phase of MI is also of
prognostic value. One study did demonstrate that increased
plasma BNP levels predict poor prognosis of patients with
old MI and a low LVEF (,45%) (35). The BNP is released
in increased amounts throughout the ventricular myocar-
dium, especially from the infarct zone, in patients with old
MI, presumably in response to increased regional wall stress
(36). Again, increased regional wall stress is believed to be
associated with adverse ventricular remodeling and poor
prognosis following AMI (18). Thus, the potential associ-
ation between plasma BNP levels and LV remodeling may
contribute to the independent prognostic value of plasma
BNP. Years after the onset of AMI, LV remodeling is still
progressive (19,20); patients with increased BNP levels in
the chronic phase of MI, as seen in the No-Reflow group,
may be at risk of progressing LV remodeling and may
consequently have a poor prognosis.
Recently, GUSTO-I investigators also reported clearly
the adverse effects of TIMI flow grade #2 after thrombo-
lytic therapy on the two-year survival based on the large
cohort (37). The results in the present study support those
in the GUSTO-I report. However, our study differs from
the GUSTO-I report in the following aspects. We investi-
gated patients recanalized by PTCA without obstructive
lesions to narrow the argument down to severe microvascu-
lar damage (no-reflow). Our follow-up period was much
longer. We studied not only mortality but also cardiac
complications in detail. We also managed to follow up
cardiac function of survivors.
Study limitations. The limitations of this study need to be
addressed. 1) The study population represents only 25% of
the patients treated for AMI at our center during the study
period, because of the strict inclusion criteria employed in
the present study. 2) The study population is relatively
small, which may limit the statistical power to detect the
predictor of long-term survival such as LVEF. 3) The TIMI
frame count was not assessed in analyzing cineangiograms.
4) Echocardiographic study was performed only at the end
of the study. Serial echocardiography would provide more
accurate evaluation of LV remodeling. In addition to
no-reflow, several factors may have contributed to advanced
LV remodeling observed in the No-Reflow group; those
include age, Killip class, enzymatic infarct size, and infarct
Table 5. Cardiac Function of the Survivors at Follow-up
No-Reflow
(n 5 15)
Reflow
(n 5 75) p Value
NYHA class
Class I 9 (60%) 58 (77%) NS
Class II 2 (13%) 13 (17%) NS
Class III 4 (27%) 0 (0%) 0.0005
Not evaluable 0 (0%) 4 (6%) NS
Echocardiographic findings
LVEDVI (ml/m2) 74.0 6 31.5 52.3 6 14.7 0.0002
LVESVI (ml/m2) 44.4 6 23.3 23.7 6 11.1 , 0.0001
LVEF (%) 41.8 6 7.8 55.5 6 11.2 , 0.0001
Plasma BNP (pg/ml) 286.8 6 512.9 73.3 6 97.6 0.002
Data are presented as the number of patients (percent) or mean value 6 SD.
BNP 5 brain natriuretic peptide; LVEDVI 5 left ventricular end-diastolic volume index; LVEF 5 left ventricular ejection
fraction; LVESVI 5 left ventricular end-systolic volume index; NS 5 not significant; NYHA 5 New York Heart Association.
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location. 5) We collected the long-term follow-up data
retrospectively; however, nearly 90% of the survivors con-
tinued visiting Ogaki Municipal Hospital at least four years
after disease onset. Thus, we obtained most of the data by
reviewing the hospital charts and by direct interview with
the patients. This enabled us to obtain the correct data in
detail and also to reduce to a minimum any bias produced by
interhospital discrepancy, such as differences in clinical
decision and treatment. Thus, we believe that the quality of
the data is sufficiently high. 6) Finally, this study represents
no-reflow in a population in the era before coronary
stenting, platelet glycoprotein IIb/IIIa receptor inhibitors,
and pharmacological treatment of no-reflow with intracoro-
nary verapamil (12,13).
Conclusions. Angiographic no-reflow phenomenon after
PTCA predicts adverse long-term outcome in patients with
AMI. Patients with no-reflow may be at risk of LV
remodeling, which leads to progressive heart failure and
cardiac death. The angiographic no-reflow phenomenon,
the simplest clinical diagnostic tool to assess myocardial
reperfusion, is therefore indispensable in early clinical deci-
sion making in treating patients with AMI.
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